Lower cognitive performance in healthy G2019S LRRK2 mutation carriers
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 9, 2011
- Accepted April 19, 2012
- First Published August 22, 2012.
Article Versions
- Previous version (August 22, 2012 - 13:02).
- You are viewing the most recent version of this article.
Author Disclosures
- Avner Thaler, MD,
- Anat Mirelman, PhD,
- Tanya Gurevich, MD,
- Ely Simon, MD,
- Avi Orr-Urtreger, MD, PhD,
- Karen Marder, MD,
- Susan Bressman, MD and
- Nir Giladi, MD
- On behalf of the LRRK2 Ashkenazi Jewish Consortium
- Avner Thaler, MD,
Travel Grant from the MDS for a congress
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
MJFF
NONE
NONE
NONE
NONE
NONE
NONE
- Anat Mirelman, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Funding provided also from The National Parkinson’s disease foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Tanya Gurevich, MD,
NONE
NONE
Funding for travel and speaker honoraria from National Parkinson foundation, Solvay pharmaceuticals, TEVA, RAFA, Medtronic, Novartis,Medison, Allergan, GlaxoSmithKline, Perrigo, Intecpharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Parkinson foundation Michael J. Fox Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Ely Simon, MD,
Takeda Pharmaceuticals - Commercial
NONE
NONE
NONE
1. Computerized neuro[sychological testing - testing system 2. Computerized neuro[sychological testing - scoring system 3. Computerized neuro[sychological testing - reporting system
NONE
NeuroTrax Corporation, CEO
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NeuroTrax Corporation
NONE
NONE
NONE
NONE
NONE
- Avi Orr-Urtreger, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Israel Science Foundation Legacy Heritage Fund,No.1922/08, Co-P.I, 2008-2011; Chief Scientist Department of Health Israel, No. 3– 4893, P.I, 2008-2011; ALS Association (USA) ALSA Grant ID 47717, Co-P.I, 2011-2014
NONE
Kahn Foundation Israel P.I.; The Michael J. Fox Foundation for Parkinson’s Research Co-P.I;
NONE
NONE
Knock-Out Mice, Baylor Colledge of Medicine, Houston, Texas
NONE
NONE
NONE
- Karen Marder, MD,
NONE
NONE
NONE
Section editor, Current Neurology and Neuroscience
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support through Columbia University from Neurosearch, NeuroSearch Sweden AB
2R56NS036630-10 (PI), 1UL1 RR024156-01(Director PCIR), 1U10NS077267-01 (CoPI),1R01NS073671-01(coI), 5R01N40068-10 (co-I),3U01AT000613-08 (coI) U01NS052592-05 (Co- I),5P20HG005535-02 (coI),5P50AG08702-22(coI, 5R01NS060113- 03
NONE
Parkinson Disease Foundation (investigator), Huntington’s Disease Society of America (investigator), Parkinson Study Group (Co-chair, executive committee) Michael J Fox foundation, CHDI (investigator)
NONE
NONE
NONE
NONE
NONE
NONE
- Susan Bressman, MD and
Scientific Advisory Board of Bachmann Strauss Dystonia and Parkinsons’s Foundation and; Michael J Fox Foundation for Parkinson’s Research; Dystonia Medical Research Foundation
NONE
NONE
NONE
THAP1 gene testing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH (5 U01 NS050095-02) 09/01/2005 – 12/31/2010, co- investigator NIH (2 P50 NS037409-10) 12/01/09-11/30/2014 , consultant
NONE
Michael J Fox Foundation for Parkinson’s Research
NONE
NONE
NONE
NONE
NONE
NONE
- Nir Giladi, MD
Serving on the Advisory Boards of UCB, Teva-Lundbeck, NeuroDerm, Intek Pharma. Chairing the Data Monitoring Safty Committee of Teva LTd.
NONE
Travel and speaking honeraria from Teva-Lundbeck, UCB, NeuroDerm, Schwartz Pharma, UCB, Merz
Associate Editor of the Journal of Neural Transmission and Current Treatment Opinion in Neurology On the Editorial Board of J Parkinson’s disease
NONE
NONE
NONE
Consultation fee to GSK, NeurDerm and Intek Pharma Speakers’ Bureaus: For Teva-Lundbeck and UCB
NONE
NONE
NONE
NONE
Israel Science Foundation NIH, USA
NONE
Michael J FOX, USA National Parkinson Foundation, USA
NONE
NONE
NONE
NONE
NONE
NONE
- From the Movement Disorders Unit, Department of Neurology (A.T., A.M., T.G., N.G.) and Genetic Institute (A.O.-U.), Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine (A.T., T.G., A.O.-U., N.G.), Tel Aviv University, Tel Aviv, Israel; School for Health Professions (A.M.), Ben-Gurion University, Beer Sheba, Israel; Department of Clinical Science (E.S.), NeuroTrax Corporation, Bellaire, Texas; Department of Neurology (E.S.), Albert Einstein College of Medicine, Bronx, New York; Columbia University (K.M.), Columbia Presbyterian Medical Center, New York, New York; and Beth Israel Medical Center (S.B.), New York, New York.
- Correspondence & reprint requests to Dr. Giladi: nirg{at}tasmc.health.gov.il
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.